Navigation Links
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Date:2/13/2009

mit the use of current therapies, including suppression of bone marrow function.

About maribavir

Maribavir is a selective, orally bioavailable Phase 3 antiviral drug with a unique mechanism of action against cytomegalovirus and a favorable clinical safety profile to date, including no evidence of renal toxicities or myelosuppression (a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets). Maribavir is a member of a new class of drugs called benzimidazole ribosides. Unlike currently available anti-CMV agents that inhibit CMV DNA polymerase, maribavir inhibits viral DNA assembly and egress of viral capsids from the nucleus of infected cells. Maribavir also has demonstrated activity in vitro against strains of CMV that are resistant to current anti-CMV therapies.

About Cytomegalovirus

CMV is a member of the herpes virus group, which includes the viruses that cause chicken pox, mononucleosis, herpes labialis (cold sores), and herpes genitalis (genital herpes). Like other herpes viruses, CMV has the ability to remain dormant in the body for long periods of time. Human CMV infection rates average between 50 percent and 85 percent of adults in the U.S. by 40 years of age, but in healthy adults causes little to no apparent illness. However, in immunocompromised individuals including cancer patients, HIV patients, and transplant patients, and in children born with primary CMV infection, CMV can lead to serious disease or death. Patients who are immunosuppressed following hematopoietic stem cell (bone marrow) or solid organ transplantation are at high risk of CMV infection. In these patients, CMV disease can lead to severe conditions such as pneumonitis or hepatitis, or to complications such as acute or chronic rejection of a transplanted organ. While currently available systemic anti-CMV agents are effective against the virus, their
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
4. ViroPharma Announces Discontinuation of HCV-796 Development
5. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
6. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. ViroPharma to Present at the Natixis Bleichroeder Conference
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
10. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
11. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... GA (PRWEB) September 18, 2014 Ben ... the Alex Ormond, Jr. Leadership Award by the Savannah ... improving healthcare and wellness throughout the nation and especially ... receive this award,” said Ben. “The Savannah Science Seminar ... 65 years and multiple generations have gone through the ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of Health ... a four-year, $1.3 million grant to the Los Angeles ... research and development of a vaccine to protect patients ... Staphylococcus aureus (MRSA). , The National ... NIH awarded the grant to LA BioMed infectious disease ...
(Date:9/18/2014)... trying to develop tools that would allow them to ... moment a neuron fires to the resulting behavior in ... are working to develop a range of new tools ... one such tool that provides a new way of ... worka collaboration between Viviana Gradinaru (BS ,05), assistant professor ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... Brophy Marcus HealthDay Reporter , WEDNESDAY, Oct. 5 ... after a kidney transplant allows some patients to cast away ... new organ, according to a small new study from the ... in the United States and while they can greatly improve ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. 5 ... tip-top health may have a greater risk of developing dementia ... Oct. 5 issue of the journal Neurology . ... simple tool for doctors to determine a person,s risk of ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- The death toll from ... risen to 18, and a total of 100 people have ... Control and Prevention reported late Tuesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
... from Mount Sinai School of Medicine have found high ... (AGEs) in infants. Excessive food AGEs, through both maternal ... children,s risk for diseases such as diabetes from a ... adults found that cutting back on processed, grilled, and ...
... (HealthDay News) -- Scientists who taught monkeys to use their ... virtual body) and to identify the texture of virtual objects ... for people who,ve suffered crippling spinal injuries. "Someday in ... technology not only to move their arms and hands and ...
... (October 5, 2011)Prostate cancer is the most common cancer ... the second leading cause of cancer-related deaths in this ... their prostate, followed by radiation therapy applied to their ... once situated. The most common technique of ...
Cached Medicine News:Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3Health News:New study shows inflammatory food toxins found in high levels in infants 2Health News:New study shows inflammatory food toxins found in high levels in infants 3Health News:Monkeys Use Brain Power, Not Hands, to 'Move' Virtual Objects 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: